Incidence of brain metastases as a first site of recurrence among women with triple receptor–negative breast cancer

This retrospective study sought to define the incidence of brain metastases as a first site of recurrence among women with triple receptor–negative breast cancer (TNBC).

[1]  C. Perou,et al.  The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases , 2011, Cancer.

[2]  S. Cole,et al.  Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study , 2010, Clinical Cancer Research.

[3]  Charles M Perou,et al.  Molecular stratification of triple-negative breast cancers. , 2010, The oncologist.

[4]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[5]  Roman Rouzier,et al.  Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  B. Leyland-Jones.  Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Hortobagyi,et al.  Breast cancer metastasis: challenges and opportunities. , 2009, Cancer research.

[8]  F. Esteva,et al.  Survival among women with triple receptor-negative breast cancer and brain metastases. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  N. Lin,et al.  Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer , 2008, Cancer.

[10]  E. Perez,et al.  Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  K. Aldape,et al.  Defining prognosis for women with breast cancer and CNS metastases by HER2 status. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Henson,et al.  Survival in patients with brain metastases from breast cancer , 2008, Cancer.

[13]  F. Heitz,et al.  Cerebral metastases (CM) in breast cancer (BC) with focus on triple-negative tumors , 2008 .

[14]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Tae Hyun Kim,et al.  Breast cancer subtypes and survival in patients with brain metastases , 2008, Breast Cancer Research.

[16]  C. Perou,et al.  The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes , 2007, Clinical Cancer Research.

[17]  K. Altundağ.  Primary breast cancer phenotypes associated with propensity for central nervous system metastases , 2006, Cancer.

[18]  Raymond R Tubbs,et al.  Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR , 2006, The American journal of surgical pathology.

[19]  R. Gelber,et al.  Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  V. Heinemann,et al.  Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer. , 2006, Breast.

[21]  C. Caldas,et al.  Molecular classification and molecular forecasting of breast cancer: ready for clinical application? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Therese Sørlie,et al.  Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. , 2004, European journal of cancer.

[23]  L. Carey,et al.  Central nervous system metastases in women after multimodality therapy for high risk breast cancer , 2004, Breast Cancer Research and Treatment.

[24]  E. Winer,et al.  CNS metastases in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Edge,et al.  Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. , 2003, The Surgical clinics of North America.

[26]  A. Twijnstra,et al.  Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma , 2002, Cancer.

[27]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[29]  O. Salazar,et al.  Breast Cancer: Metastatic Patterns and Their Prognosis , 1988, Southern medical journal.

[30]  Yoshiaki Tsukada,et al.  Central nervous system metastasis from breast carcinoma autopsy study , 1983, Cancer.

[31]  William H. Hartmann,et al.  The World Health Organization Histological Typing of Breast Tumors—Second Edition , 1982 .

[32]  A. Buzdar,et al.  Estrogen receptor: a prognostic factor in breast cancer. , 1981, Cancer.

[33]  Black Mm,et al.  Nuclear structure in cancer tissues. , 1957 .

[34]  K. Hess,et al.  DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. , 2011, The oncologist.

[35]  Y. Gong.  Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study: O'Brien KM, Cole SR, Tse C-K, et al (Univ of North Carolina, Chapel Hill; et al) Clin Cancer Res 16:6100-6110, 2010§ , 2011 .

[36]  L. Carey.  Directed therapy of subtypes of triple-negative breast cancer. , 2010, The oncologist.

[37]  G. Azabdaftari.  Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype , 2009 .

[38]  The world Health Organization Histological Typing of Breast Tumors--Second Edition. The World Organization. , 1982, American journal of clinical pathology.

[39]  M. Black,et al.  Nuclear structure in cancer tissues. , 1957, Surgery, gynecology & obstetrics.